Trexquant Investment LP Verve Therapeutics, Inc. Transaction History
Trexquant Investment LP
- $7.59 Billion
- Q3 2024
A detailed history of Trexquant Investment LP transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Trexquant Investment LP holds 555,502 shares of VERV stock, worth $2.99 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
555,502
Previous 523,393
6.13%
Holding current value
$2.99 Million
Previous $2.55 Million
5.25%
% of portfolio
0.04%
Previous 0.04%
Shares
4 transactions
Others Institutions Holding VERV
# of Institutions
186Shares Held
73.3MCall Options Held
85KPut Options Held
183K-
Alphabet Inc. Mountain View, CA12.3MShares$66.4 Million4.09% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$35.6 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.96MShares$26.7 Million0.01% of portfolio
-
State Street Corp Boston, MA4.25MShares$22.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.01MShares$21.5 Million0.0% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $322M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...